Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert S. who wrote (9081)	3/10/1999 9:45:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Robert S, I recognized your non-rosy opinion as fair and smart lurking pending to jump if prospects get better.

To: Robert S. who wrote (9081)	3/10/1999 11:21:00 PM
From: Cacaito	Respond to of 17367

xoma.com This one shows quite good evidence in other gram-negative infections. Cystic Fibrosis program: most organisms are gram-negative, evidence is increasing in vitro and in vivo. The trauma study will quickly confirm results from meningo, recruitment is much faster (but they need many more patients). If the market does not recognized these, I will. Good bpi results in meningo trials means a $billion drug market. $32 in 32 months (I have being posting same number for 20 months).